Healthcare
Hangzhou Tigermed Consulting Co., Ltd.(HNGZY)
Live Price
Offline$4.00
+0.00% today
1Y Change
+0.00%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $40.73B
- Revenue Growth
- +3.5%
- EPS Growth
- +121.3%
- Dividend Yield
- 0.5%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Hangzhou Tigermed Consulting Co., Ltd. (HNGZY) is a Healthcare stock with a market cap of $40.73B and listed on OTC. The stock last traded around $4.00 and up 0.0% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +3.5%, EPS growth of +121.3%, a dividend yield of 0.5%. What stands out right now is revenue +3.5%, EPS +121.3%, free cash flow +22.0% with operating margin 18.0% and ROIC 3.9%. The dividend is present but secondary, with a yield around 0.5%. Valuation already assumes a fairly strong business story at P/E 58.5 and price/sales 5.8. Stock Foundry combines HNGZY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.5% vs +7.6% peer median
Operating Margin
Near sector median
+18.0% vs +19.4% peer median
P/E
Above sector median
58.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +3.5% and EPS at +121.3%, with operating margin around 18.0%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.5%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 28, 2026 | โ | +0.0% | +0.0% | +0.0% |
2026 Mar 27, 2026 | โ | +0.0% | +0.0% | +0.0% |
2025 Oct 29, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Edge
HNGZY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
HNGZY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
HNGZY Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for HNGZY and SPY.
Company Overview
Hangzhou Tigermed Consulting Co., Ltd.
Other OTC
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
- Leadership
- Xiaoping Ye D.Phil
- IPO Date
- Jul 11, 2022
- Employees
- 10.2k
- Street Address
- F18, Building A โ Shengda Science Park
- Mailing
- Hangzhou, 310051
- Region
- Hangzhou, CN
- Reporting Currency
- USD
- Investor Line
- 86 57 1288 87227
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 58.5
- EV/EBITDA
- 25.2
- Price/Sales
- 5.8
- Price/Book
- 2.2
Growth
- Revenue
- +3.5%
- EPS
- +121.3%
- Free Cash Flow
- +22.0%
Profitability
- Gross Margin
- 26.6%
- Operating Margin
- 18.0%
- Net Margin
- 10.9%
- ROE
- 3.7%
- ROIC
- 3.9%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 2.30
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.